CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. The rise in the plasma collection
4.1.2. Growing geriatric population across the globe
4.1.3. Increase in the prevalence of respiratory diseases
4.1.4. Growing use of immunoglobulins in various therapeutic areas
4.2. Market Restraints & Challenges
4.2.1. The emergence of recombinant alternatives
4.2.2. High cost and limited reimbursement
4.2.3. Stringent government regulations
4.3. Market Opportunities
4.3.1. Growing number of patients with haemophilia
CHAPTER 5. GLOBAL PLASMA FRACTIONATION MARKET – BY PRODUCT
5.1. Introduction
5.2. Immunoglobulin
5.2.1 Intravenous Immunoglobulin (IVIG)
5.2.2 Subcutaneous Immunoglobulin (SCIG)
5.2.3 Other Immunoglobulins
5.3 Coagulation Factor Concentrates
5.3.1 Factor VIII
5.3.2 Factor IX
5.3.3 Von Willebrand Factor
5.3.4 Prothrombin Complex Concentrate
5.3.5 Fibrinogen Concentrates
5.3.6 Factor XIII
5.4 Albumin
5.5 Protease Inhibitors
5.6 Other Plasma Products
CHAPTER 6. GLOBAL PLASMA FRACTIONATION MARKET – BY APPLICATION
6.1. Neurology
6.2. Haematology
6.3. Immunology
6.4. Critical care
6.5. Hemato-Oncology
6.6. Pulmonology
6.7. Rheumatology
6.8. Others
CHAPTER 7. GLOBAL PLASMA FRACTIONATION MARKET – BY END USER
7.1. Hospital &clinics
7.2. Clinical research laboratories
7.3. Research institutes
CHAPTER 8. GLOBAL PLASMA FRACTIONATION MARKET - BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.2.4. Costa Rica
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Chile
8.3.4. Columbia
8.3.5. Others
8.4. Europe
8.4.1. U.K.
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Russia
8.4.7. Netherlands
8.4.8. Switzerland
8.4.9. Poland
8.4.10. Others
8.5. APAC
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. South Korea
8.5.5. Australia & New Zealand
8.5.6. Malaysia
8.5.7. Singapore
8.5.8. Others
8.6. Middle East & Africa
8.6.1. UAE
8.6.2. Saudi Arabia
8.6.3. Iran
8.6.4. Iraq
8.6.5. Qatar
8.6.6. South Africa
8.6.7. Algeria
8.6.8. Morocco
8.6.9. Nigeria
8.6.10. Egypt
8.6.11. Others
CHAPTER 9. GLOBAL PLASMA FRACTIONATION MARKET - COMPANY
PROFILES
9.1. China Biologic Products, Inc.
9.2. CSL Limited
9.3. Octapharma AG
9.4. Shire Plc.
9.5. Kedrion Biopharma
9.6. LFB S.A.
9.7. Sanquin
9.8. Grifols, S.A.
9.9. Japan blood Products Organization
9.10. Green Cross Corporation
9.11. Bio Products Laboratory
9.12. Shanghai Raas Blood Products Co., Ltd
9.13. Biotest AG
9.14. Beijing Tiantan Biological Products Corp
9.15. Bharat Serums and Vaccines Limited
CHAPTER 10. GLOBAL PLASMA FRACTIONATION MARKET - COMPETITIVE
LANDSCAPE
10.1. Market Share Analysis
10.2. Strategies adopted by top companies
10.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 11. MARKET INSIGHTS
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
CHAPTER 12. APPENDIX
12.1. List of Tables
12.2. List of Figures
